Active, not recruitingPhase 3NCT05644561

Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG)

Studying Adult-onset myasthenia gravis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Alexion Pharmaceuticals, Inc.
Intervention
Ravulizumab(drug)
Enrollment
12 enrolled
Eligibility
All sexes
Timeline
20232028

Study locations (10)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05644561 on ClinicalTrials.gov

Other trials for Adult-onset myasthenia gravis

Additional recruiting or active studies for the same condition.

See all trials for Adult-onset myasthenia gravis

← Back to all trials